Pharma Validation Manager's Guide to Dry Ice Cleaning in cGMP Environments

This guide is for pharmaceutical validation managers, cleanroom facility managers, supplier qualification leads, and operations teams at pharma manufacturing and biotech facilities evaluating dry ice cleaning as part of cleaning specification reviews. We’ll cover cGMP procedure framework adoption, supplier qualification audit pathway, validation cycle protocol, and batch record integration.

This is the technical-and-procedural backbone you need before initiating supplier qualification or cleaning specification review for dry ice as a candidate method.

Why pharma adoption is different

Pharmaceutical and biotech facilities operate under regulatory scrutiny that adjacent industries don’t:

• GMP / cGMP frameworks define what cleaning is acceptable, how it’s validated, and how it’s documented
• Supplier qualification is a lengthy formal process before any external supplier can deliver services
• Validation cycles require multiple successful runs before procedure adoption
• Audit posture scrutinises cleaning procedures, supplier records, and batch-level cleaning evidence
• Cross-contamination risk is a primary regulatory concern with potentially significant compliance consequences

This means dry ice cleaning adoption in pharma takes longer, requires more documentation, and survives more scrutiny than in adjacent regulated industries (food, beverage). We’ve worked through supplier qualification at multiple pharma sites; the process is rigorous but achievable.

What dry ice cleaning is — for the validation manager

Dry ice cleaning uses pellets of solid CO₂ accelerated by compressed air to physically remove surface contamination. The pellet sublimates (transitions from solid directly to gas) on impact, leaving no residue.

Key cGMP-relevant properties:

• Food-grade CO₂ standard. Pharma-grade or instrument-grade sourcing available on request for cleaning specifications requiring it.
• No residue. The pellet sublimates entirely; there’s nothing left on the surface to test for or carry over.
• No water, no chemistry. No moisture, no detergent, no rinse cycle. Eliminates carry-over risk for cleaning agents.
• Non-abrasive at correctly tuned pressure. Substrate surfaces preserved.
• Documented procedure — every clean produces structured records suitable for batch-level integration.

What it doesn’t replace:

• Closed-system CIP for product-contact pipelines
• SIP cycles for sterilisation requirements
• Specific chemical sanitisation where regulatory requires chemical agent

What it adds:

• Cleaning of external equipment surfaces, packaging machinery, ovens, oven walls, conveyor backs
• Hot-cleaning capability where applicable (tablet press tooling, drying ovens, coating pans)
• Cleaning between batches without chemical carry-over
• Validated procedure for surfaces where chemical isn’t validated

The cGMP procedure framework

Standard procedure document structure for a cGMP customer:

1. Purpose and scope. What equipment, what contamination, what frequency, what acceptable post-cleaning state.

2. Cleaning agents. CO₂ pellet specification (food-grade, pharma-grade where required), pellet size, pellet supplier qualification.

3. Equipment specification. Dry ice cleaning rig specification, compressor specification, nozzle specification, monitoring equipment.

4. Cleaning procedure. Step-by-step procedure with pressure setting per surface, sequence, dwell time, atmospheric monitoring.

5. Acceptance criteria. Visual standard, ATP swab specification (where applicable), surface verification.

6. Documentation. Per-clean record format including operator, date, time, equipment, deviations, results.

7. Operator training. Qualifications required, training records, requalification cycle.

8. Deviation handling. What constitutes a deviation, escalation pathway, corrective action.

9. Validation. Initial validation cycle requirements, ongoing monitoring, requalification triggers.

10. References. Regulatory references, internal SOP references, master cleaning specification.

Procedure documents are co-developed with your QA and validation functions. We provide templates; you customise to your site’s specific framework.

Supplier qualification pathway

Standard sequence we follow with pharma customers:

Phase 1 — Initial qualification (Weeks 1-2).

• NDA execution
• Supplier questionnaire response
• Insurance certificates and qualifications submitted
• Reference customer details (under NDA)
• Initial documentation pack delivered

Phase 2 — Document review (Weeks 3-6).

• Procedure document review by your QA
• Equipment specification review by your engineering
• Operator qualification review by your training function
• Cleaning specification alignment workshop

Phase 3 — Validation cycles (Weeks 7-14).

• 3-cycle minimum (most sites require 5-7) demonstration runs
• Per-cycle documentation review
• ATP swab studies (where applicable)
• Validation report compilation and review
• Validation report sign-off

Phase 4 — Supplier audit (Weeks 15-16).

• On-site audit at our depot or service location
• Quality system review
• Operator competency review
• Final supplier qualification report

Phase 5 — Contract activation.

• Master service agreement
• Per-batch quality requirements
• Service level agreements
• Annual audit cycle established

For sites with strict change-control processes, the full pathway can run 16-24 weeks. For sites with established supplier-qualification frameworks, 8-12 weeks is typical.

Validation cycle protocol

Standard validation cycle for a new cleaning application:

Cycle 1 — Procedure trial. First run of the proposed procedure with parallel existing chemical clean as fallback. Both procedures validated to the existing cleaning specification. Result: procedure works, fallback unused.

Cycle 2 — Procedure repeat. Second run with same procedure to validate consistency. Result: consistent outcome.

Cycle 3 — Worst-case demonstration. Procedure run on a worst-case batch (highest contamination, longest interval since last clean, etc.) to validate robustness. Result: procedure handles worst-case.

Cycles 4-7 — Routine validation. Standard production cleans with documented results. Statistical analysis of results across cycles.

Validation report compilation. All cycle data compiled into validation report. Statistical analysis. Comparison to existing chemical-clean baseline.

Validation report sign-off. Your QA/validation function signs off the procedure for ongoing use.

We support each step with operator deployment, equipment, documentation and on-site QA support during validation cycles. Your QA function leads the validation; we provide the cleaning capability.

Equipment compatibility

Pharma equipment we routinely clean:

Equipment	Application	Validation status
Tablet press tooling	Hot-clean between batches	Validated at multiple sites
Coating pans	Between batches	Validated
Drying ovens	Between batches	Validated
Mill chambers	Between batches	Validated
Reactor exteriors	Periodic cleaning	Validated
Packaging line equipment	Daily / between batches	Validated
Filler heads (where chemistry not validated)	Between batches	Site-specific
Cleanroom equipment exteriors	Periodic	Validated
HVAC components (filters, ducts)	Periodic	Validated
Lyophilisers	Between cycles	Site-specific

What we don’t do:

• Internal pipework / closed-system CIP (continues per existing procedure)
• Direct product-contact surfaces during production (always change-over)
• Sterile barrier system internal cleaning (specialised; case-by-case)

Batch record integration

Per-clean records produced as part of standard practice:

• Operator
• Date / time / shift
• Equipment cleaned
• Cleaning agent batch (CO₂ pellet supplier batch)
• Procedure version
• Pressure setting
• Atmospheric monitoring readings
• Visual acceptance verification
• ATP swab results (where applicable)
• Deviations and corrective actions
• Operator signature
• QA review signature

Format: structured PDF with photo log, suitable for batch record attachment. Can be delivered as XML feed for direct integration into MES / batch record systems on request.

Cross-contamination risk management

A primary regulatory concern. Our practice:

• Equipment dedication. Where appropriate, cleaning rig dedicated per site or per product line to eliminate cross-site contamination potential.
• CO₂ pellet sourcing. Food-grade or pharma-grade per site requirement. Per-batch certificate of analysis available.
• Operator gowning. Per-site gowning protocol followed. Operators qualified per site.
• HEPA filtration. Vacuum capture during cleaning for any cross-contamination-sensitive applications.
• Procedure validation. Cross-contamination risk assessment as part of validation pack.

For sites with high cross-contamination sensitivity (multi-product manufacturing, cytotoxic facility, etc.) we run dedicated equipment per site as standard.

Pricing structure for pharma

Pharma engagement typically follows one of three models:

Per-cleaning fee. Per-asset or per-zone cleaning charge. Typically $3,500-$12,000 per scheduled cleaning depending on equipment and validation requirements. Suitable for facilities with low-frequency cleaning needs.

Annual program contract. Fixed annual fee for an agreed cleaning program. Typically $80K-$300K depending on equipment scope and frequency. Suitable for facilities with regular cleaning requirements.

Project-based engagement. Specific equipment installation cleaning, equipment qualification cleaning, audit-prep cleaning. Typically $8K-$50K per project. Suitable for one-off needs.

All pharma engagement is preceded by supplier qualification. Pricing models are confirmed during the qualification process.

Common questions for pharma adoption

Have you been qualified at other pharma sites? Yes — multiple Australian pharma facilities have completed supplier qualification with us. Reference customer details available on request after NDA.

Will it pass an FDA / TGA audit? When properly validated and documented, yes. Procedure documentation and validation pack support audit posture; we don’t claim regulatory approval but our documentation aligns with FDA/TGA expectations.

What about process validation, not just cleaning validation? Cleaning validation is what we focus on. Process validation is your QA’s responsibility; we provide the cleaning capability and documentation.

Can you support facility validation (qualification of new equipment)? Yes — facility qualification cleaning is one of our common pharma applications. Particularly common during new equipment installation and commissioning.

Do you have experience with high-potency / cytotoxic facilities? Yes — limited but growing experience. Engagement requires more rigorous PPE, dedicated equipment, and additional protocol development. Email office@dryiceblasters.com.au to discuss specific requirements.

Will you sign our specific quality agreement? Yes — we sign customer-specific quality agreements during contract activation. Standard terms covered by our master service agreement; customer-specific requirements addressed in supplementary agreement.

How to engage

Three paths:

1. Initial discovery conversation. Email office@dryiceblasters.com.au with site details and primary application. We’ll arrange an NDA-protected initial conversation.

2. Pharma Validation Whitepaper download. 26-page PDF covering procedure templates, supplier qualification pathway, validation cycle protocol. Use internally before engaging.

3. Site visit and proposal. Following initial discovery, we run a site visit (NDA-protected) to scope specific applications and develop a tailored proposal.

Most pharma customers go via the whitepaper download first. It gives the validation function a complete operational framework to evaluate against existing cleaning specifications.

Final thoughts

Pharma adoption of dry ice cleaning is a longer process than other industries — but the regulatory rigour produces a robust outcome. Once a procedure is qualified at your site, it operates as a documented, auditable cleaning method that integrates with your existing cGMP framework rather than replacing it.

The economics for pharma sites that adopt the method tend to be better than the per-cleaning cost suggests, because:

• Equipment downtime for cleaning falls (CIP supplemented rather than replaced for closed surfaces)
• Cleaning agent inventory reduces (chemical SKUs eliminated for surfaces dry ice cleans)
• Cross-contamination risk falls (no chemical carry-over)
• Validation overhead reduces (one validated procedure replaces multiple chemical-specific procedures)

For a complete operational framework before initiating supplier qualification, download the Pharma Validation Whitepaper. For initial discovery conversation, email office@dryiceblasters.com.au.